ArticleDiscover oncology2025
LncRNA LINC02381/miR-133b axis promotes tumorigenesis and predicts survival in pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLncRNA LINC02381 has emerged as a promising tumor biomarker; however, its involvement in the pathogenesis of pancreatic cancer remains unexplored at this time. The objective of this study is to elucidate the regulatory effect of LINC02381 in pancreatic cancer and to ascertain its potential prognostic significance.
methodsThe clinical characteristics of the pancreatic cancer patients included were meticulously analyzed, with a total of 112 pancreatic cancer and 75 normal tissue samples collected. Real-time quantitative polymerase chain reaction (RT-qPCR) was applied to detect LINC02381 and miR-133b expression. The proliferative activity of pancreatic cancer cells was verified via in vitro CCK-8 and Transwell assays. The targeting relationship between LINC02381 and miR-133b was discussed by dual-luciferase reporting assay and RIP assay, and the prognostic potential of LINC02381 in pancreatic cancer was predicted by Kaplan-Meier survival curve analysis and Cox regression analysis.
resultsThe level of LINC02381 was dramatically increased in pancreatic cancer tissues and cells, while miR-133b level was decreased. LINC02381 knockdown suppressed the proliferation behavior, migratory ability, and invasive processes of pancreatic cancer cells (Panc-1, BxPC-3, ASP-1, and SUIT-2). Moreover, miR-133b is the downstream target of LINC02381, exhibiting a negative correlation with LINC02381 expression.
conclusionElevated levels of LINC02381 are associated with diminished survival outcomes in pancreatic cancer patients, suggesting its potential as a prognostic biomarker for this malignancy. These findings warrant further investigation to elucidate the role of LINC02381 in pancreatic cancer progression and patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.